Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of IMM2510 Plus IMM27M in Advanced Hepatocellular Carcinoma
CTR20262431Phase 2Active
- Sponsor
- ImmuneOnco
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM2510, IMM27M in hepatocellular carcinoma (HCC), sponsored by ImmuneOnco. Started Jul 2026; status: active.
02
Drugs
IMM2510IMM27M
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20262431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262431.